{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:46:55Z","timestamp":1784677615268,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.det.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:53:31Z","timestamp":1729371211000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Innovation in Botulinum Toxins"],"prefix":"10.1016","volume":"43","author":[{"given":"Reema","family":"Rashied","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2024.08.004_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/toxins15020082","article-title":"Cosmetic treatment using botulinum toxin in the oral and maxillofacial area: a narrative review of esthetic techniques","volume":"15","author":"Hong","year":"2023","journal-title":"Toxins"},{"issue":"12","key":"10.1016\/j.det.2024.08.004_bib3","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1167\/iovs.17-22576","article-title":"The use of botulinum toxin to treat infantile esotropia: a systematic review with meta-analysis","volume":"58","author":"Issaho","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.det.2024.08.004_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/toxins13010058","article-title":"Botulinum toxin: an update on pharmacology and newer products in development","volume":"13","author":"Choudhury","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.det.2024.08.004_bib5","series-title":"Textbook of cosmetic dermatology. 5th, Illustrated","first-page":"459","article-title":"Textbook-of-cosmetic-dermatology","author":"Hexsel","year":"2017"},{"issue":"10","key":"10.1016\/j.det.2024.08.004_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00128071-200304100-00005","article-title":"Botulinum toxin a (botox cosmetic): a review of its use in the treatment of glabellar frown lines","volume":"4","author":"Frampton","year":"2003","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl","key":"10.1016\/j.det.2024.08.004_bib7","doi-asserted-by":"crossref","first-page":"e32371","DOI":"10.1097\/MD.0000000000032371","article-title":"Early development history of Botox (onabotulinumtoxinA)","volume":"102","author":"Scott","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.det.2024.08.004_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/CCID.S156851","article-title":"Botulinum neurotoxin formulations: overcoming the confusion","volume":"11","author":"Samizadeh","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.det.2024.08.004_bib11","unstructured":"Available at: https:\/\/www.xeominaesthetic.com\/?gclid=CjwKCAjwreW2BhBhEiwAavLwfMVDvYuM6MomWHIttFzKcHTpxZXMbT4UNGeVge33HF7wQruwX6GpQBoC7asQAvD_BwE. Accessed 6 September 2024."},{"issue":"4","key":"10.1016\/j.det.2024.08.004_bib12","doi-asserted-by":"crossref","first-page":"ojab036","DOI":"10.1093\/asjof\/ojab036","article-title":"High-dose neuromodulators: a roundtable on making sense of the data in real-world clinical practice","volume":"3","author":"Fabi","year":"2021","journal-title":"Aesthetic Surg J Open Forum"},{"key":"10.1016\/j.det.2024.08.004_bib13","doi-asserted-by":"crossref","first-page":"ojac031","DOI":"10.1093\/asjof\/ojac031","article-title":"Important considerations in the high-dose toxins discussion","volume":"4","author":"Brown","year":"2022","journal-title":"Aesthetic Surg J Open Forum"},{"issue":"2","key":"10.1016\/j.det.2024.08.004_bib14","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J\u00a0Clin Aesthetic Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.08.004_bib15","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/asj\/sjac157","article-title":"Safety, pharmacodynamic response, and treatment satisfaction with OnabotulinumtoxinA 40 U, 60 U, and 80 U in subjects with moderate to severe dynamic glabellar lines","volume":"42","author":"Joseph","year":"2022","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.det.2024.08.004_bib16","series-title":"Neurotoxins and fillers in facial esthetic surgery","first-page":"19","article-title":"Neurotoxins","author":"Perenack","year":"2019"},{"issue":"7","key":"10.1016\/j.det.2024.08.004_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/toxins13070494","article-title":"Botulinum toxin type a for glabellar frown lines: what impact of higher doses on outcomes?","volume":"13","author":"Kaufman-Janette","year":"2021","journal-title":"Toxins"},{"issue":"11","key":"10.1016\/j.det.2024.08.004_bib19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/asj\/sjac157","article-title":"Safety, pharmacodynamic response, and treatment satisfaction with onabotulinumtoxina 40 u, 60 u, and 80 u in subjects with moderate to severe dynamic glabellar lines","volume":"42","author":"Joseph","year":"2022","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.det.2024.08.004_bib20","doi-asserted-by":"crossref","unstructured":"Cox SE, Joseph JH, Fagien S, et\u00a0al. Safety, pharmacodynamic response, and treatment satifaction with onabotulinumtoxina 40 u, 60 U, and 80 U in subjects with moderate to severe dynamic glabellar lines. Presented at: ASDS meeting; 2020; Virtual.","DOI":"10.1016\/j.toxicon.2020.11.368"},{"issue":"4","key":"10.1016\/j.det.2024.08.004_bib21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/DSS.0000000000002846","article-title":"A\u00a0multicenter study to evaluate subject satisfaction with two treatments of abobotulinumtoxina a year in the glabellar lines","volume":"47","author":"Schlessinger","year":"2021","journal-title":"Dermatol Surg"},{"issue":"10","key":"10.1016\/j.det.2024.08.004_bib22","first-page":"1052","article-title":"IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines","volume":"20","author":"Kerscher","year":"2021","journal-title":"J\u00a0Drugs Dermatol JDD"},{"key":"10.1016\/j.det.2024.08.004_bib23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2147\/IJGM.S406563","article-title":"DAXI (DaxibotulinumtoxinA) \u2013 an innovative approach for frown lines","volume":"16","author":"Mussarat","year":"2023","journal-title":"Int J Gen Med"},{"issue":"11","key":"10.1016\/j.det.2024.08.004_bib24","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","article-title":"Group and the E 001\/EV 002 S. efficacy and safety of prabotulinumtoxina for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"issue":"9","key":"10.1016\/j.det.2024.08.004_bib28","first-page":"980","article-title":"AbobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines: a randomized, dose-escalating, double-blind study","volume":"20","author":"Joseph","year":"2021","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"18","key":"10.1016\/j.det.2024.08.004_bib29","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s40265-021-01631-w","article-title":"Overview of daxibotulinumtoxina for injection: a novel formulation of botulinum toxin type A","volume":"81","author":"Solish","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.det.2024.08.004_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00266-022-03018-y","article-title":"Efficacy and safety of botulinum toxin type a for treatment of glabellar lines: a network meta-analysis of randomized controlled trials","volume":"47","author":"Li","year":"2023","journal-title":"Aesthetic Plast Surg"},{"issue":"1","key":"10.1016\/j.det.2024.08.004_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/DSS.0000000000002463","article-title":"A\u00a0large, open-label, phase 3 safety study of daxibotulinumtoxina for injection in glabellar lines: a focus on safety from the SAKURA 3 study","volume":"47","author":"Green","year":"2021","journal-title":"Dermatol Surg"},{"issue":"9","key":"10.1016\/j.det.2024.08.004_bib32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/DSS.0000000000003852","article-title":"Bridging the gap: sustained treatment effect of glabellar lines with twice-a-year treatment with DaxibotulinumtoxinA","volume":"49","author":"Dover","year":"2023","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.det.2024.08.004_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/asj\/sjz003","article-title":"Liquid formulation of abobotulinumtoxina: a 6-month, phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines","volume":"40","author":"Ascher","year":"2020","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.det.2024.08.004_bib34","article-title":"Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow\u2019s feet)","year":"2022","journal-title":"Galderma"},{"key":"10.1016\/j.det.2024.08.004_bib37","author":"Global"},{"issue":"3","key":"10.1016\/j.det.2024.08.004_bib39","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/PRS.0000000000001032","article-title":"The efficacy and safety of liquid-type botulinum toxin type a for the management of moderate to severe glabellar frown lines","volume":"135","author":"Kim","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.det.2024.08.004_bib40","doi-asserted-by":"crossref","first-page":"107492","DOI":"10.1016\/j.toxicon.2024.107492","article-title":"Treatment of moderate-to-severe glabellar lines with relabotulinumtoxina, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-1 phase 3 trial","volume":"237","author":"Solish","year":"2024","journal-title":"Toxicon"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:04:51Z","timestamp":1755695091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0733863524000767"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.08.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation in Botulinum Toxins","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}